Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

NCT02535286 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Richter Syndrome

Interventions

DRUG: Umbralisib
BIOLOGICAL: ublituximab
BIOLOGICAL: TG-1501

Sponsor

TG Therapeutics, Inc.

Collaborators

[object Object]